Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report) issued its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.01), Zacks reports. The business had revenue of $0.69 million during the quarter, compared to analysts’ expectations of $3.99 million. Lexicon Pharmaceuticals had a negative net margin of 147.38% and a negative return on equity of 39.56%.
Here are the key takeaways from Lexicon Pharmaceuticals’ conference call:
- SONATA-HCM enrollment was completed significantly ahead of plan, with the Phase 3 trial including both obstructive and non-obstructive HCM patients. Lexicon expects top-line results in the first quarter of 2027.
- Lexicon expects to satisfy the FDA’s requirements for a ZYNQUISTA (sotagliflozin) resubmission after Steno-1 reaches the required exposure level by the end of August; the company currently anticipates filing the NDA in the fourth quarter of 2026. DKA rates in Steno-1 remain similar to standard of care and below prior inTandem-trial levels.
- Second-quarter revenue fell to $0.7 million from $28.9 million a year earlier, largely because the prior-year period included $27.5 million in Novo Nordisk licensing revenue. Lexicon reported a $31.8 million net loss, versus net income of $3.3 million in the prior-year quarter, while R&D spending increased due to SONATA.
- Lexicon strengthened its liquidity, ending June with $190.6 million in cash and short-term investments and replacing its prior debt with a Hercules Capital facility that provided $55 million at closing, with up to $45 million more potentially available subject to conditions.
- Novo Nordisk continues to advance LX9851, Lexicon’s first-in-class oral ACSL5 inhibitor for obesity, in Phase 1 development. Lexicon could receive another $10 million milestone payment later this year.
Lexicon Pharmaceuticals Stock Up 4.7%
NASDAQ LXRX traded up $0.11 on Friday, hitting $2.47. 3,085,741 shares of the stock were exchanged, compared to its average volume of 2,836,652. The company has a quick ratio of 18.77, a current ratio of 18.80 and a debt-to-equity ratio of 0.24. Lexicon Pharmaceuticals has a fifty-two week low of $1.02 and a fifty-two week high of $2.68. The company has a market cap of $1.10 billion, a PE ratio of -16.47 and a beta of 1.08. The company has a 50-day moving average price of $2.20 and a 200-day moving average price of $1.86.
Trending Headlines about Lexicon Pharmaceuticals
- Positive Sentiment: Lexicon completed enrollment in the pivotal Phase 3 SONATA-HCM study of sotagliflozin for hypertrophic cardiomyopathy, exceeding its 500-patient enrollment target. Top-line results remain expected in the first quarter of 2027, providing a potentially significant future catalyst. Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
- Positive Sentiment: The company said its activities to resubmit the ZYNQUISTA NDA for glycemic control in adults with type 1 diabetes are nearing completion, with resubmission anticipated in the fourth quarter of 2026. Phase 1 development of obesity candidate LX9851 is also continuing through partner Novo Nordisk, and Lexicon could receive an additional $10 million milestone payment as early as later this year. Lexicon Pharmaceuticals Q2 2026 Earnings Call Transcript
- Positive Sentiment: Lexicon reported $190.6 million in cash and investments at June 30, supported by $96.2 million in stock-sale proceeds, giving it additional resources to fund clinical development. A Hercules Capital facility also provides up to $100 million in potential financing, subject to conditions.
- Neutral Sentiment: Management emphasized disciplined capital allocation and early commercial planning for its late-stage pipeline. However, the principal value drivers remain dependent on successful clinical results and regulatory approval.
- Negative Sentiment: Second-quarter revenue fell to approximately $0.7 million from $28.9 million a year earlier because the prior-year period included substantial Novo Nordisk licensing revenue. The company posted a net loss of roughly $31.8 million, or $0.07 per share, versus net income of $3.3 million in the prior-year quarter. Revenue also came in below analyst expectations, while research and development spending rose to $17.4 million as SONATA-HCM costs increased. Lexicon Pharmaceuticals Reports Q2 Loss, Lags Revenue Estimates
Wall Street Analysts Forecast Growth
Several analysts have recently issued reports on the company. Zacks Research cut Lexicon Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday. Weiss Ratings raised Lexicon Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, July 23rd. Finally, Citigroup upped their price target on Lexicon Pharmaceuticals from $2.30 to $3.10 and gave the stock a “buy” rating in a report on Monday, May 11th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $4.55.
Get Our Latest Stock Report on Lexicon Pharmaceuticals
Institutional Investors Weigh In On Lexicon Pharmaceuticals
Hedge funds and other institutional investors have recently modified their holdings of the company. Hudson Bay Capital Management LP purchased a new stake in Lexicon Pharmaceuticals during the 4th quarter worth about $116,000. Quarry LP acquired a new position in shares of Lexicon Pharmaceuticals during the 4th quarter worth about $101,000. State of Wyoming increased its holdings in shares of Lexicon Pharmaceuticals by 610.4% in the 4th quarter. State of Wyoming now owns 60,571 shares of the biopharmaceutical company’s stock valued at $70,000 after acquiring an additional 52,045 shares during the last quarter. Bank of America Corp DE increased its holdings in shares of Lexicon Pharmaceuticals by 80.1% in the 3rd quarter. Bank of America Corp DE now owns 57,804 shares of the biopharmaceutical company’s stock valued at $78,000 after acquiring an additional 25,707 shares during the last quarter. Finally, Jefferies Financial Group Inc. acquired a new stake in shares of Lexicon Pharmaceuticals during the 3rd quarter worth about $131,000. 74.70% of the stock is currently owned by institutional investors and hedge funds.
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon’s approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.
The company’s most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy.
Read More
- Five stocks we like better than Lexicon Pharmaceuticals
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
- Solventum Nears Inflection Point As It Begins to Unlock Value
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
